Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Presenter: Joseph O’Donoghue, Ph.D. | Attending Physicist, Memorial Sloan-Kettering Cancer Center
Radiopharmaceutical therapies exploit the tumor targeting ability of small molecules, peptides, or antibodies to treat solid cancers with cytotoxic radiation while limiting damage to normal tissues.
During this webinar, the presenter will discuss:
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
Attending Physicist, Memorial Sloan-Kettering Cancer Center
Dr. O’Donoghue is a medical physicist with a long-standing interest in the imaging and treatment of malignant disease by molecular-targeted radionuclides. Dr. O’Donoghue’s work includes radiation dosimetry, radiobiological modeling, experimental and clinical nuclear imaging, kinetic analysis and tumor response assessment for radiolabeled antibodies and small molecules. In the lab he has investigated the application of ex-vivo analysis featuring digital autoradiography and immunohistochemistry to examine the microdistribution of targeted radionuclides in patient tumors.
